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Background: Potential cardiovascular (CV) risks of testosterone replacement therapy (TRT) are currently a topic of
intense interest. However, no studies have addressed CV risk as a function of the route of administration of TRT.
Methods: Two meta-analyses were conducted, one of CV adverse events (AEs) in 35 randomized controlled trials
(RCTs) of TRT lasting 12 weeks or more, and one of 32 studies reporting the effect of TRT on serum testosterone
and dihydrotestosterone (DHT).
Results: CV risks of TRT: Of 2,313 studies identified, 35 were eligible and included 3,703 mostly older men who
experienced 218 CV-related AEs. No significant risk for CV AEs was present when all TRT administration routes were
grouped (relative risk (RR) = 1.28, 95% confidence interval (CI): 0.76 to 2.13, P = 0.34). When analyzed separately, oral
TRT produced significant CV risk (RR = 2.20, 95% CI: 1.45 to 3.55, P = 0.015), while neither intramuscular (RR = 0.66, 95%
CI: 0.28 to 1.56, P = 0.32) nor transdermal (gel or patch) TRT (RR = 1.27, 95% CI: 0.62 to 2.62, P = 0.48) significantly altered
CV risk. Serum testosterone/DHT following TRT: Of 419 studies identified, 32 were eligible which included 1,152 men
receiving TRT. No significant difference in the elevation of serum testosterone was present between intramuscular or
transdermal TRT. However, transdermal TRT elevated serum DHT (5.46-fold, 95% CI: 4.51 to 6.60) to a greater magnitude
than intramuscular TRT (2.20-fold, 95% CI: 1.74 to 2.77).
Conclusions: Oral TRT produces significant CV risk. While no significant effects on CV risk were observed with either
injected or transdermal TRT, the point estimates suggest that further research is needed to establish whether
administration by these routes is protective or detrimental, respectively. Differences in the degree to which serum
DHT is elevated may underlie the varying CV risk by TRT administration route, as elevated serum dihydrotestosterone
has been shown to be associated with CV risk in observational studies.
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Testosterone replacement therapy (TRT) is being utilized
at a rapidly increasing rate, with 1.6 billion dollars in sales
in the US in 2011 [1]. Proven benefits for older men with
low testosterone (T) levels include increases in muscle
strength, exercise capacity, bone mineral density (BMD),
libido and insulin sensitivity [2,3]. Meta-analysis through* Correspondence: Stephen.borst@va.gov
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from TRT: 1) polycythemia, 2) an increased number of
prostate-related events, and 3) a small reduction in high
density lipoprotein (HDL) cholesterol. Prostate events
consist of the combined incidence of elevated prostate-
specific antigen (PSA), prostate biopsy necessitated by
results of digital rectal exam, increased urinary symptoms
and prostate cancer [4]. A meta-analysis by Calof et al.
shows no evidence that TRT increases prostate cancer
(odds ratio =1.09 with no trend toward significance), when
considered as an independent outcome [4]. However, the
cardiovascular (CV) risk of TRT is controversial [5,6].d. This is an Open Access article distributed under the terms of the Creative
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may produce CV risks. In their randomized controlled
trial (RCT) of transdermal T gel administration, Basaria
et al. reported a very high incidence of CV adverse events
(AEs) in treated subjects (21%) compared to placebo (5%)
resulting in cessation of the trial [7]. More recently, Vigen
et al., in a retrospective study of 8,709 hypogonadal men
with a history of recent coronary angiography, reported
a higher risk of the combined endpoints of myocardial
infarction (MI), stroke and all-cause mortality in those
who received any form of TRT (25.7%) compared to
those who did not (19.9%) [8]. Another observational
study by Finkle et al. evaluated 55,000 patients and
reported a more than two-fold greater risk of MI in men
who had received a TRT prescription [9]. Similarly, a
meta-analysis by Xu et al. of CV AEs in 27 RCTs
administering TRT (reported through 2012) found that
TRT produced a significantly greater number of CV
AEs in TRT-treated participants compared to placebo
(odds ratio (OR) 1.54, 95% CI 1.09 to 2.18) and also
made the disturbing observation that these AEs were
under-reported in industry-sponsored studies [10]. How-
ever, the statistical methods employed in the latter study
were not appropriate for low event-rate meta-analysis [11].
In contrast, Corona et al. [12] published a meta-analysis of
75 studies of TRT using less stringent inclusion criteria and
found no evidence of CV risk (OR = 1.07 for all CV AEs;
OR = 1.01 for serious CV AEs). In response to these
reports, in 2014, the US Food and Drug Administration
[13], the US Veteran’s Administration [14] and the Endo-
crine Society [15] have all issued advisories regarding CV
AEs resulting from TRT.
In contrast with the above reports, some of which
indicate that TRT may be associated with [8,9] or may
cause [7,10] increased CV events, there is an extensive
literature supporting the CV benefits of adequate levels of
endogenous T and TRT. In older men, low T is associated
with increased CV risk and increased all-cause mortality
[16]. Several studies have shown that TRT is beneficial in
populations of older men with CV disease. English et al.
have shown that TRT improves exercise capacity in men
with angina [17]. In addition, Toma and colleagues [18]
have published a meta-analysis demonstrating improved
New York Heart Association (NYHA) class, six minute
walk time and peak oxygen consumption after TRT in
men with systolic heart failure [18]. Furthermore, in a
large retrospective cohort study of more than 6,000 intra-
muscular TRT users and matched controls, Baillargeon
et al. reported no increase in CV events in myocardial
infarction hospitalization rates in all TRT-treated subjects
and reduced rates in those who were in the quartile with
the highest risk factors for CV disease [19].
One potential explanation for these apparently conflict-
ing observations is that the CV risk/benefit ratio mayvary by the route of TRT administration. Testosterone
can be administered by intramuscular injection of long-
acting T esters, transdermally by patch or gel and orally
as testosterone undecanoate (TU). Different routes of
administration are typically associated with different doses,
different time courses of serum androgen elevation and dif-
ferent relative levels of dihydrotestosterone (DHT) relative
to testosterone. Transdermally and orally administered T
are exposed to a high degree of 5-alpha reductase activity
present in the skin [20] and liver [21], respectively, possibly
increasing serum DHT relative to testosterone, which
may affect CV risk. Shores et al. recently reported that
serum DHT is independently and positively associated
with incident CV disease [22], incident stroke [23], and
all-cause mortality [22]. In contract, in a cohort of 1,032
elderly men followed for a median of nine to ten years,
neither circulating T nor free T were associated with the
latter adverse outcomes.
The main purpose of this meta-analysis was to assess
whether the incidence of CV events is affected by the
mode of TRT administration. Our secondary purpose
was to determine if there is a differential elevation of T
versus DHT based on route of TRT administration. We
postulate that the latter may be a potential mechanism
for differential CV effects.
Methods
Data sources and searches
This meta-analysis follows the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
checklist [see Additional file 1]. Two expert authors
searched for and selected the studies, agreed upon the
eligibility of each study and extracted information from
the selected trials (SB, FY). We systematically searched
PubMed until 31 May 2014 using two search strategies:
1) (“testosterone” or “androgen”) and (random*) and
“trial” and 2) “testosterone” and “clinical trials”. Studies
of men, published in English were selected and the
search was supplemented by a search of the World Health
Organization trial registry and by a manual search of
bibliographies of identified studies (SB and FY). To
identify studies reporting the elevation of serum T and
DHT following TRT, we performed a supplemental
search using the terms: “testosterone” and “DHT” and
(“injection” or “gel” or “patch” or “oral”) that included
all TRT clinical trials in men because few studies report
DHT concentrations before and after TRT.
Study selection
CV risks following TRT
We included only placebo-controlled RCTs of TRT that
reported CV related events for both the TRT and placebo
arms. We excluded trials where testosterone secretion
was experimentally suppressed prior to initiation of TRT
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In order to assess the long-term, rather than the acute,
effects of TRT, we included only trials lasting 12 weeks
or more. Initially, we intended to exclude RCTs that only
reported AEs necessitating study withdrawal, however this
turned out to be a fine distinction and so we included
any RCT that reported CV events by treatment arm. In
order to ensure that we did not include more than one
study using the same data set, we checked for duplica-
tion based on authorship, study description, number of
participants, and participant characteristics. Where dupli-
cation occurred, we used the report containing the most
comprehensive description of AEs.
Elevation of serum T and DHT following TRT
Few placebo-controlled RCTs report both serum T and
DHT before and after treatment. For this reason, we
broadened our search to include all TRT trials that
reported both serum T and DHT, before and after treat-
ment, regardless of study duration or whether the study
was blinded. We have recently shown that commercially
available methods for measuring DHT by immunoassay
are invalid [24]. For this reason, we also excluded one
study where DHT was measured by immunoassay [25].
We also removed any duplication of studies as described
above.
Outcome
The primary outcome was composite CV events because
we anticipated too few events to allow for analysis by
individual event type. CV events were defined as any-
thing reported as such in the original study. In cases
where authors sent us a table of all AEs, we (SEB and
AW - Cardiologist) defined CV AEs using International
Statistical Classification of Disease (ICD) 10 codes [see
Additional file 2]. CV events in individual studies are
listed in Additional file 3. The secondary outcome was
elevation of serum T and DHT following TRT adminis-
tration by different routes (intramuscular, transdermal
(patch or gel) or oral).
Data extraction and quality assessment
Data for CV AEs and elevation of serum T and DHT
were extracted by trial arm by SB and FY. Event classi-
fication was checked by a cardiologist (AW). Reviewers
(SB and FY) used an established tool to evaluate the
quality of each trial [26] [see Additional file 4 and
Additional file 5]. If the trial did not report CV AEs or
did not do so by treatment arm, we contacted the
authors twice by email to ask for additional information
[see Additional file 6]. Studies were excluded if CV
event incidence could not be determined with the above
method.Statistical methods
CV events analysis
It is important to note that this collection of studies
involves low event-rate randomized binomial trials. Since
the trials involve diverse interventions, random effects
are mandatory, whether or not a Cochran Q test fails to
reject homogeneity (Borenstein et al. [27], section titled
‘Model should not be based on the test for heterogeneity’).
In addition, commonly used methods based on inverses
of variance estimators such as the DerSimonian-Laird
method are not valid in this arena. The Cochrane
Handbook [28], section 16.9, states ‘Methods that should
be avoided with rare events are the inverse-variance
methods (including the DerSimonian and Laird (DL) [29]
random-effects method). Xu et al. [10] used a fixed effects
meta-regression with inverse variance weights in their
previous meta-analysis, and as such, this was not an ac-
ceptable approach when event rates are low. Furthermore,
compared with a random effects model, a fixed effects
model makes the strong assumption that the true effect
size for all studies is identical and the inference from a
fixed effects model is conditional and limited to the stud-
ies included in the meta-analysis [30]. The methodology
we employ is the sample size weighted random effects
method of Shuster et al. [11], specifically designed for low
event-rate meta-analysis, and which has been vetted on
nearly 40,000 low event scenarios. Given the issues with
low event-rate meta-analysis, ignored in Xu et al., it is crit-
ically important to reanalyze those data in this paper. Note
that we employ RR, the estimate of the ratio of failure
rates, rather than the OR, the ratio of the odds of failure.
RR and OR are very similar when event rates are low, but
RRs are far easier to understand.
Analysis of serum T and DHT levels
For laboratory levels, we used a minor modification of
the patient weighted random effects method of Shuster
[31], using the more conservative t-distribution (degrees
of freedom = number of studies - 1) instead of the normal
approximation. In our experience this is a better large
sample approximation. Means are sample-weighted. The
individual study fold changes were analyzed (not the
ratio of the summary post-test estimate to the summary
pre-test estimate).
Results
Study selection and characteristics for analysis of CV risks
The initial search yielded 2,313 publications, of which
197 were subjected to further scrutiny. As shown in
Figure 1, we subsequently identified 35 unique publica-
tions of placebo-controlled RCTs of TRT in men that
reported CV events and met our search criteria. The study
design and patient characteristics across these trials are
summarized in Table 1. The 35 studies of TRT include
Articles retrieved for detailed examination (n = 
197)    
Articles excluded (no CV events by trial arm, 
intervention < 12 week, not RCT, no control 
group) (n = 146)
Articles found from WHO Clinical Trial registry 
(n = 1)    
Articles found in bibliography of selected articles 
(n =4) 
Articles excluded because of no clarification of 
CV events from authors (n = 21)   
Final inclusion for meta-analysis (n = 35)
Articles identified in PubMed searches
(n =2313)   
Articles deemed not relevant based on title or 
abstract (n = 2116)    
Figure 1 Selection process for placebo-controlled randomized clinical trials (RCTs) of testosterone replacement therapy (TRT) on CV events.
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or chronic diseases. Of the 35 trials, 16 studies adminis-
tered TRT intramuscularly, 15 transdermally (10 gel and 5
patch), and 4 orally. The mean duration of treatment was
11.9 months.
Risk of CV events based on route of TRT
Of the 3,703 subjects, 2,114 receiving TRT had 131 CV-
related events (6.2%), while 1,589 receiving placebo had
87 (5.5%) CV-related events. Two trials were stopped
early, one because of AEs in the TRT arm [7] and one
because a beneficial effect of TRT was ‘not foreseeable’
[32]. Additional file 3 shows a comprehensive list of the
type and severity of the 218 CV events (if specified) in
the TRT and placebo groups.
As shown in Figure 2, among patients receiving any
form of TRT, the estimated RR for CV events was 1.28
(95% CI 0.76 to 2.13, P = 0.34) which was not statistically
significant. However, CV event rates varied by mode of
TRT administration. Specifically, oral TRT resulted in a
significant increase in CV events (estimated RR = 2.20,
95% CI 1.45 to 3.35, P = 0.015). In contrast, neither intra-
muscular TRT (estimated RR = 0.66, 95% CI 0.28 to 1.56,
P = 0.32) nor transdermal (patch or gel) TRT (estimated
RR = 1.27, 95% CI 0.62 to 2.62, P = 0.48) significantly
affected CV events.Re-analysis of Xu et al. [10]: Using the same patient-
weighted method [31], the estimated relative risk for CV
AEs is 1.59 (95% CI = 0.90 to 2.57), P = 0.059, not quite
statistically significant, whereas Xu et al. [10] using inverse
variance weighted methods (against the advice of the
Cochrane Handbook), reported a point estimate of 1.54
(95% CI =1.09 to 2.18).
Route of TRT and elevation of serum T and DHT Levels
As shown in Figure 3, the initial search yielded 419 pub-
lications, of which 56 were subjected to further scrutiny.
We subsequently identified 31 unique publications that
met our criteria and which included 1,176 men who
received TRT (see Table 2). Elevation of serum DHT, but
not T, was significantly affected by TRT administration
mode (see Table 3). Specifically, intramuscular TRT ele-
vated serum T and DHT to a roughly similar degree. In
contrast, transdermal TRT elevated DHT to a signifi-
cantly greater degree (5.46-fold, 95% CI 4.51 to 6.60)
than intramuscular TRT (2.20-fold, (95% CI 1.74 to
2.77). Only four oral TRT studies were identified that
reported both T and DHT, and the data were insufficient
for statistical analysis. However, oral TRT appeared to
produce a post-treatment serum T that was similar with
other administration routes and very high post-treatment
serum DHT values.
Table 1 Characteristics of placebo-controlled randomized clinical trials of testosterone replacement therapy (TRT) reporting CV events




Serum T at entry Health status
Amory 2004 [32] i.m. 100 mg TE/week 36 months 71 ± 4 (SD) 24 24 302 ± 48 (SD) ng/dL hypogonadal
Aversa 2010 [33] i.m. 1,000 mg TU/12 week 24 months 58 ± 10 (SD) 40 10 259 ± 48 (SD) ng/dL hypogonadal
Borst 2014 [34] i.m. 125 mg TE/week 12 months 69.2 ± 8.0 (SD) 31 29 264 ± 92 (SD) ng/dL hypogonadal
Caminiti 2009 [35] i.m. 1,000 mg TU/8 week 4.5 months 66 to 76 35 35 230 ± 180 (SD) ng/dL hypogonadal, heart failure
Ferrando 2002 [36] i.m. 100 mg TE/week 6 months 67 ± 3 (SD) 7 5 <480 ng/dL eugonadal
Hackett 2014 [37] i.m. 1000 mg TU/6 to 12 weeks 7.5 months 18 to 80 97 102 301 ± 11 (SD) ng/dL hypogonadal, type 2 diabetes
Hall 1996 [38] i.m. 250 mg TE/4 weeks 9 months 60.8 ± 9.7 (SD) 17 18 458 ± 187 (SD) ng/dL eugonadal, rheumatoid arthritis
Ho 2011 [39] i.m. 1,000 mg TU/10 to 14 weeks 24 months ≥40 60 60 <345 ng/dL low normal T
Hoyos 2012 [40] i.m. 1,000 mg TU/6 weeks 4.5 months 49 ± 12 (SD) 33 34 388 ± 152 (SD) ng/dL eugonadal, obese, sleep apnea
Kalichenko 2010 [41] i.m. 1,000 mg TU/6 to 12 weeks 7.5 months 49 to 53 113 71 <345 ng/dL low normal T, metabolic syndrome
Kenny 2004 [42] i.m. 200 mg TE/3 weeks 3 months 81 ± 5 (SD) 6 5 410 ± 112 (SD) ng/dL mild cognitive impairment
Sih 1997 [43] i.m. 200 mg TC/2 weeks 12 months 65 ± 7 (SD) 17 15 233 ± 20 (SD) ng/dL hypogonadal
Svartberg 2004 [44] i.m. 250 mg TE/4 weeks 6 months 64 ± 6.5 (SD) 15 14 590 ± 164 (SD) ng/dL eugonadal, COPD
Svartberg 2008 [45] i.m. 1,000 mg TU/6 to 12 weeks 12 months 69 ± 5 (SD) 19 19 239 ± 54 (SD) ng/dL hypogonadal
Sheffield-Moore 2011 [46] i.m. 100 mg TE/week 5 months 73 ± 8 (SD) 8 8 <500 ng/dL eugonadal
Tan 2013 [47] i.m. 1,000 mg TU/8 weeks 12 months 53.8 ± 8.3 (SD) 56 58 <345 ng/dL low normal T
*Basaria 2010 [7] gel 100 to 150 mg T/day 6 months* 74 ± 5 (SD) 106 103 250 ± 57 (SD) ng/dL hypogonadal, mobility limited
Brockenbrough 2006 [48] gel 100 mg T/day 6 months 58.9 ± 14.9 (SD) 19 21 218 ± 64 (SD) ng/dL hypogonadal, renal disease
Glintborg 2013 [49] gel 50 to 100 mg T/day 6 months 62 to 72 20 18 <210 ng/dL hypogonadal, obese
Hildreth 2013 [50] gel 25 to 50 mg T/day 12 months 66.6 ± 5.8 (SD) 96 47 294 ± 38 (SD) ng/dL hypogonadal
Jones 2011 [51] gel 60 mg T/day 12 months 37 to 77 108 112 265 ± 75 (SD) ng/dL hypogonadal, metabolic syndrome
Kaufman 2011 [52] gel 20 to 80 mg T/day 6 months 53.6 ± 9.5 (SD) 234 40 mean =294 ng/dL hypogonadal
Kenny 2010 [53] gel 50 mg T/day 12 to 24 months 79.9 ± 7.3 (SD) 69 62 380 ± (SD) ng/dL eugonadal, osteoporosis
Marin 1993 [54] gel 125 mg T/day 9 months 56.7 ± 2.2 (SD) 11 10 434 ± 23 (SD) ng/dL eugonadal, obese
Spitzer 2012 [55] gel 100 to 300 mg T/day 3.5 months 55.1 ± 8.3 (SD) 70 70 248 ± 62 (SD) ng/dL hypogonadal, erectile dysfunction
Srinivas-Shankar 2010 [56] gel 50 mg T/day 6 months 73.7 ± 5.7 (SD) 138 136 313 ± 89 (SD) ng/dL low normal T, frail
English 2000 [17] patch 5 mg T/day 3 months 69 ± 2 (SD) 25 25 390 ± 22 (SD) ng/dL eugonadal, stable angina
Malkin 2006 [57] patch 5 mg T/day 12 months 63.1 ± 10.7 (SD) 37 39 400 ± 152 (SD) ng/dL eugonadal, heart failure
Merza 2005 [58] patch 5 mg T/day 6 months 63 ± 9 (SD) 20 19 242 ± 95 (SD) ng/dL hypogonadal
Nair 2006 [59] patch 5 mg T/day 24 months 61 to 72 27 31 bioavailable T <103 ng/dL hypogonadal
Snyder 2001 [60] patch 6 mg T/day 36 months 71.3 ± 5.8 (SD) 54 54 <475 ng/dL eugonadal


















Table 1 Characteristics of placebo-controlled randomized clinical trials of testosterone replacement therapy (TRT) reporting CV events (Continued)
Copenhagen study 1986 [62]a oral 600 mg micronized T/day 8 to 62 months 24 to 79 134 87 not measured alcoholic cirrhosis
Emmelot-Vonk 2008 [63] oral 80 mg TU/day 6 months 67.1 ± 5.0 (SD) 120 117 316 ± 54 (SD) ng/dL low normal T
Legros 2009 [64] oral 80 to 240 mg TU/day 12 months 58.6 ± 5.7 (SD) 237 79 free T <7.5 ng/dL hypogonadal



















Figure 2 Forest plot of all placebo-controlled randomized clinical trials (RCTs) reporting the pooled effect of testosterone replacement
therapy (TRT) and the individual effects by TRT administration route on CV events.
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This meta-analysis of 35 eligible studies and more than
3,700 patients receiving TRT is the largest consolidation
of RCT data thus far. Our main finding is that no signifi-
cant increase in CV event risk was noted among studies
of various TRT administration routes when analyzed
together. Further, when the risk of CV events was ana-
lyzed based on the mode of administration, only oralTRT was associated with elevated CV risk when com-
pared with placebo. The increase in CV risk resulting
from transdermal TRT and the decrease in CV risk seen
with intramuscular TRT did not achieve statistical signifi-
cance. A second important finding in this meta-analysis is
that the oral and transdermal administration methods of
TRT are associated with greater DHT elevations than
intramuscular administration. Because there is emerging
Articles retrieved for detailed examination         
(n = 56)    
Articles excluded (pre-post serum T-DHT not 
reported) (n = 23)
Articles found from WHO Clinical Trial registry 
(n = 0)    
Articles excluded because T and/or DHT were 
not measured by reliable methods (n = 2)   
Final inclusion for systematic review (n = 31)
Articles identified in PubMed searches
(n = 419)   
Articles deemed not relevant based on title or 
abstract (n = 363)    
Figure 3 Selection process for clinical trials reporting both serum testosterone (T) and dihydrotestosterone (DHT) concentrations before
and after testosterone replacement therapy (TRT).
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(rather than serum T) and adverse CV events, these two
findings may have important implications for our current
understanding of the mechanisms of CV risk in TRT
recipients.
Mode of administration and CV risk
Our finding that there are varying CV risks based on the
type of TRT formulation helps reconcile seemingly dispar-
ate observations across various studies regarding testoster-
one’s CV effects. While three prior meta-analyses suggested
no significant increase in CV risk across TRT RCTs [4-6], a
more recent meta-analysis by Xu et al. [10] indicated higher
CV risk with TRT. The present meta-analysis is the most
extensive thus far. Although we included all reported CV
AEs in this meta-analysis, we have included newer studies
exclusive to this review which may reflect less publication
bias, more rigorous patient screening practices and more
attention to the reporting of hard CV endpoints rather than
nonspecific CV events that may have driven AE rates in
previous studies.
The increased CV risk of the oral formulation subgroup
is a novel finding in our analysis. While no significant
effects on CV risk were observed with either injected or
transdermal TRT, the point estimates suggest that further
research is needed to establish whether administration by
these routes is protective or detrimental, respectively. To
the best of our knowledge, differing CV risk specific tovarying testosterone formulations has not been previously
reported.
DHT elevation and increased CV risk
The greater elevation of DHT that occurs with oral or
transdermal TRT may be due to the high expression of
5-α reductase in skin [20] and liver [21] in comparison
to lower 5-α reductase in skeletal muscle [89]. The find-
ing of differential DHT elevation may be critical to our
understanding of adverse CV risk, because elevated serum
DHT (not elevated T) has recently been found to be asso-
ciated with CV risk in several observational studies.
Shores et al. published two studies of 1,032 older men
which reported significant associations between the serum
DHT concentration and both the 10-year rate of incident
ischemic stroke [23] and the 9-year rate of incident CV
disease and all-cause mortality [16] (see Figure 4). Inter-
estingly, similar relationships did not exist for serum total
or free T, suggesting that CV risk resulting from TRT may
result from the 5α-reduction of T to DHT. In both studies
by Shores et al., the lowest risk was associated with a
serum DHT concentration of approximately 60 ng/dL,
while greater risk was associated with both higher and
lower DHTconcentrations.
In Figure 4, the left panel represents data from our
meta-analysis showing the elevation of serum DHT with
intramuscular, transdermal and oral TRT. In the center
and right panels, we have superimposed that data on top
Table 2 Characteristics of testosterone replacement therapy (TRT) trials reporting both serum testosterone (T) and dihydrotestosterone (DHT) concentrations
before and after treatment
Author/Year Study type Mode Dose Duration Age Subjects in TRT group Serum T at entry Health status
Amory 2004 [32] RCT i.m. 100 mg TE/week 36 months 71 ± 4 (SD) 24 302 ± 48 (SD) ng/dL hypogonadal
Arver 1997 [65] open-label i.m. 266 mg TE/26 days 3 weeks 58 ± 10 (SD) 27 121 ± 100 (SD) ng/dL hypogonadal
Bhasin 2012 [66] RCT i.m. 125 mg TE/week 5 months 40 ± 7 (SD) 12 519 ng/dL (mean) eugonadal
Borst 2014 [34] RCT i.m. 125 mg TE/week 12 months 69.2 ± 8.0 (SD) 31 264 ± 92 (SD) ng/dL hypogonadal
Lakshman 2010 [67] RCT i.m. 125 mg TE/week 5 months 65.6 ± 4.3 (SD) 11 581 ± 168 (SD) ng/dL eugonadal
Raynaud 2008 [68] open-label i.m. 250 mg TE/3 weeks 12 months 41.8 ± 12.4 (SD) 32 43 ng/dL (mean) hypogonadal
Shubert 2003 [69] open-label i.m. 250 mg TE/3 weeks 12 months 31.9 ± 2.5 (SD) 14 63.6 ng/dL ±14 (SD) hypogonadal
Wang 2010 [70] open-label i.m. 750 mg TU/4 to 10 weeks 21 months >18 117 320 ng/dL ±111 (SD) low normal T
Brockenbrough 2006 [48] RCT gel 10 mg T/day 6 months 58.9 ± 14.9 (SD) 19 218 ± 64 (SD) ng/dL hypogonadal, renal disease
Cherrier 2003 [71] RCT gel 50-100 mg T/day 6 months 34 to 70 12 320 ± 90 (SD) ng/dL low normal T
Chiang 2007 [72] RCT gel 50 mg T/day 3 months 20 to 75 17 213 ± 158 (SD) ng/dL hypogonadal
Dean 2004 [73] open-label gel 50 mg T/day 9 months 58.5 (mean) 257 247 ng/dL (mean) hypogonadal
Di Luigi 2012 [74] open-label gel 50 mg T/day 1.25 month 31.3 ± 7.5 (SD) 10 72 ng/dL (mean) hypogonadal
Juang 2014 [75] RCT gel 100 mg T/day 3.5 months 24 to 51 14 302 ± 37 (SD) ng/dL hypogonadal, osteoporosis
Kenny 2010 [53] RCT gel 50 mg T/day 12 months 79.9 ± 7.3 (SD) 69 380 ± 179 (SD) ng/dL eugonadal, osteoporosis
Marin 1993 [54] RCT gel 125 mg T/day 9 months 56.7 ± 2.2 (SD) 10 455 ± 23 (SD) ng/dL eugonadal, obese
Mazer 2005 [76] RCT gel 59 mg/day 2 weeks 52.4 ± 12.2 (SD) 28 226 ± 110 (SD) ng/dL hypogonadal
Page 2011 [77] RCT gel 75 mg T/day 6 months >50 27 204 ng/dL (mean) hypogonadal, BPH
Swerdloff 2000 [78] open-label gel 100 mg T/day 3 months 51.3 (mean) 76 280 ng/dL (mean) hypogonadal
Wang 2000 [79] no placebo group gel 100 mg T/day 2 weeks 26 to 59 10 179 ± 41 (SD) ng/dL hypogonadal
Wang 2011 [80] open-label gel 60 mg T/day 4 months 51.5 ± 12.7 (SD) 135 215 ± 84 (SD) ng/dL hypogonadal
Ahmed 1988 [81] no placebo group patch 15 mg T/day 6 to 8 weeks 34 to 54 5 45 ± 12 (SD) ng/dL hypogonadal
Bals-Pratch 1988 [82] not stated patch 10 to 15 mg T/day 14 months 31 to 37 7 189 ng/dL (mean) hypogonadal
Behre 1999 [83] open-label patch 2.4 to 3.6 mg T/day 7 years 35.9 ± 9.8 (SD) 11 147 ± 37 (SD) ng/dL hypogonadal
Cunningham 1989 [84] placebo-controlled patch 15 mg T/day 8 weeks 33 to 66 12 43 ± 11 (SD) ng/dL hypogonadal
Mazer 2005 [76] open-label patch 5 mg T/day 2 weeks 28 to 71 28 215 ± 110 (SD) ng/dL hypogonadal
Meikle 1992 [85] not stated patch 12.6 mg T/day single dose 24 to 66 6 161 ± 27 (SD) ng/dL hypogonadal
Raynaud 2008 [68] open-label patch 2.5 mg T/day 12 months 40.7 ± 10.5 (SD) 131 43 ng/dL (mean) hypogonadal


















Table 2 Characteristics of testosterone replacement therapy (TRT) trials reporting both serum testosterone (T) and dihydrotestosterone (DHT) concentrations
before and after treatment (Continued)
Roth 2011 [87] open-label oral 400 mg TU/day 1 day 18 to52 11 405 ± 14 (SD) ng/dL eugonadal
Schubert 2003 [69] open-label oral 160 mg TU/day 12 months 34.5 ± 3.9 (SD) 13 63.6 ng/dL ±14 (SD) hypogonadal
Van Coevorden 1986 [88] RCT oral 240 mg TU/day 12 weeks 40 ± 11 (SD) 19 161 ± 86 (SD) ng/dL hypogonadal, renal insufficiency

































increase in DHT (95% CI)
Intramuscular 8 9.27 (5.68 to 12.85) 23.11 (15.38 to 34.72) 2.91 (2.19 to 3.86) 1.02 (0.69 to 1.34) 1.62 (1.2 to 2.19) 2.20 (1.74 to 2.77)
Transdermal
(patch and gel)
20 7.28 (6.09 to 8.42) 16.69 (12.62 to 21.98) 2.53 (1.83 to 3.50) 0.99 (0.78 to 1.20) 3.43 (2.37 to 4.98) 5.46 (4.51 to 6.60)
Gel 13 8.90 (7.67 to 10.13) 18.3 (15.18 to 23.12) 1.98 (1.70 to 2.30) 1.19 (0.93 to 1.46) 3.81 (2.57 to 5.63) 5.12 (4.07 to 6.45)
Patch 7 4.20 (2.78 to 5.23) 9.73 (4.01 to 23.62) 4.43 (2.99 to 6.54) 0.62 (0.36 to 0.88) 2.16 (0.68 to 6.87) 6.61 (3.08 to 14.16)
Orala 4 6.66 21.88 2.80 0.90 3.92 4.46
(14.05, 2.9, 5.6, 4.1) (59.2, 5.70, 7.6, 14.96) (4.20, 2.20, 1.4, 3.6) (1.1, 1.8, 0.30, 0.41) (9.89, 3.30, 1.13, 1.35) 9.0, 1.8, 3.8, 3.3
aEffects of oral TRT on T and DHT concentrations were not statistically analyzed because only four studies were identified that met our a priori inclusionary criteria, which resulted in sufficient data. For oral studies, the
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Figure 4 Comparison of DHT levels after testosterone treatment with DHT levels that are associated with cardiovascular disease risk.
Left panel. Testosterone-induced elevation of DHT in the eight RCTs of testosterone injection, twenty RCTs of transdermal administration and
four RCTs of oral testosterone administration shown in Table 2. Transdermal administration causes a greater elevation of serum DHT. Center
panel. Data from panel 1 is overlayed on observational data from Shores et al. showing the relationship between serum DHT and 10 year risk of incident
ischemic stroke in older men. The solid line represents the estimated hazard ratio (HR) and the shaded area depicts the 95% confidence interval. All models
are adjusted for age (reprinted with permission from Shores et al. Clin Endocrinol (Oxf) 2014. doi: 10.1111/cen.12452 [22]. Right panel. Data from panel
1 is overlayed on observational data from Shores et al. showing the relationship between serum DHT and incident cardiovascular disease risk. The solid
line represents the estimated hazard ratio (HR) and the shaded area depicts the 95% confidence intervals. All models are adjusted for age. (Reprinted with
permission from Shores et al. J Clin Endocrinol Metab 2014, 99:2061-2068. [23]). DHT, dihydrotestosterone; RCT, randomized controlled trial.
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by Shores et al. Taken together, these data appear to
indicate that intramuscular TRT elevates the serum
DHT concentration into a range that is associated with
reduced CV disease (CVD) and stroke risks. In contrast,
transdermal and oral TRT appear to elevate serum DHT
into a range that is associated with unchanged CVD risk
and increased ischemic stroke risk.Limitations
Reporting of AEs may be open to interpretation and so
may vary somewhat among trials. Using the most serious
CV events (stroke, myocardial infarction, and CV-related
death) might be more unambiguous. Because of very long
follow-up periods, such events are common enough to
assess in observational studies [16,22,23]. However, due
to shorter study duration, serious CV events are not
common enough to study in clinical trials of TRT. As a
result, our analyses are based on all CV events, serious
or not.
The data on oral TRT must be interpreted with caution,
since only four studies met the inclusion criteria. Of those,
two had very low rates of CV events in both the treated
and placebo groups [61,64] and one study had very high
post-treatment serum T concentrations [32], possibly
due to the presence of liver disease in the study subjects.
The latter study was not included in the analysis of
TRT-induced elevations of T/DHT because DHT was
not measured. However, among the four studies analyzed
for T/DHT, there was considerable variation in serum
concentrations. Variation may result from the fact thatserum T concentrations are not sustained following oral
TRT and the time of blood acquisition is therefore critical.
Two studies included in the analysis of CV risk were
stopped early. One study of oral TRT was stopped because
of lack of evidence for efficacy unrelated to CV [32] and
one study of gel TRT was stopped early for excess CV
events in the group receiving testosterone [7]. The first
study, whose stopping was uninfluenced by CV has no
bias associated with early stopping. The second, may actu-
ally be associated with a slight bias estimate away from
the null, actually strengthening the null conclusion. There
is no way to adjust for this without serial patient level data
and the exact stopping rules used.
Interpretation of the data on TRT-induced elevations
of T and DHT may be limited by the fact that DHT was
assayed by several methods in the included studies. The
latter include mass spectroscopy (MS) based methods
and various radioimmunoassays (RIAs). MS-based assays
provide highly accurate measurements of DHT. RIAs
are specific for DHT [90] but the values are somewhat
higher than those obtained with MS-based assays [91].
The enzyme-linked immunosorbant assay (EIA) for
DHT is not valid as we have recently shown [24] and
studies using this method were excluded. The current
analysis is based on clinical trials that have a high rate
of compliance. An additional limitation in extending
our findings to a clinical setting is that compliance may
be lower. Schoenfeld et al. have shown that TRT gel
adherence is only 37.4% at six months [92]. Similarly,
Donatucci et al. [93] reported that at three months, adher-
ence to transdermal TRT was 52% and adherence to
injected TRT was 32%.
Borst et al. BMC Medicine 2014, 12:211 Page 13 of 16
http://www.biomedcentral.com/1741-7015/12/211Potential cardiovascular benefits of testosterone
Although this paper encompasses a discussion of adverse
CV risk of TRT, assessment of the CV risk–to-benefit
should be considered. Numerous studies have demon-
strated positive CV effects of TRT. English et al. [17]
have shown that, in men with stable angina, treatment
with low-dose T (5 mg/day by patch) for 12 weeks caused
a significant 17% increase in time to 1-mm ST segment
depression during treadmill exercise testing. Stout et al.
[94] have shown that TRT administration to men with
chronic heart failure increases maximal oxygen consump-
tion (VO2max) and improves physical performance. Toma
et al. [18] published a meta-analysis of the four studies
showing that TRT improved exercise capacity in heart
failure patients. Empen et al. [95] reported that T defi-
ciency is associated with impaired arterial flow-mediated
dilation (FMD), a marker of vascular endothelial function.
Cardiovascular improvement with TRT is thought to result
from increased coronary blood flow, peripheral vasodila-
tion, positive remodeling of skeletal muscle and reduced
insulin resistance, without marked effects on left ventricu-
lar ejection fraction [18].Conclusions
The potential CV risks of TRT are currently being
debated. This updated meta-analysis indicates oral TRT
produces increased CV risk, while TRT administered by
all routes may cause an increase in CV adverse events,
but the effect is not statistically significant. On the
latter point, a definitive answer awaits further clinical
trials. More studies are also needed to assess whether
increased CV risk occurs with the transdermal formula-
tions and decreased CV risk with the intramuscular for-
mulation. This early indicator that intramuscular T
may be safer than transdermal TRT may be surprising,
considering that intramuscular TRT doses are typically
several-fold higher than transdermal doses. However,
our data indicate that transdermal TRT produces a
significantly greater elevation of serum DHT than intra-
muscular T, possibly due to the expression of 5-alpha
reductase in the skin. Interestingly, serum DHT con-
centrations following intramuscular TRT correspond to
DHT levels that are associated with reduced CV risk in
other large observational studies, suggesting that: 1)
CV risks of TRT administration may result from exces-
sive elevation of serum DHT; and 2) intramuscular
TRT may produce less CV risk than transdermal or oral
TRT. Given our unique findings, future RCTs, meta-
analyses and retrospective database studies evaluating
the health risks associated with TRT should carefully
control for the change in serum DHT and evaluate the
TRT administration route as potential confounding factors
in their data analysis.Additional files
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